Nitto Avecia Celebrates a Year of Strong Growth after Acquiring Girindus America’s Contract Manufacturing Business

With more than 20 years in the manufacturing business, Nitto Avecia is marking the one year anniversary of its acquisition of Girindus America’s Contract Manufacturing Business.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Detlef Rethage, President of Nitto Avecia, says “our clients are pleased with the integration of the Cincinnati, OH and Milford, MA sites, as well as the additional services, capacity and resources Nitto Avecia now offers. Our goal in 2014 is to grow our

Cincinnati, Ohio (PRWEB) February 05, 2014

Nitto Denko Avecia Inc., an industry leader in the development and manufacture of innovative oligonucleotide therapeutics, is proud to announce its one year anniversary of the acquisition of Girindus America’s contract manufacturing business. This acquisition in early 2013 strengthened Nitto Avecia’s position as the leader in the oligonucleotide contract manufacturing market while adding new capabilities, including small molecule API production, radiolabeling, conjugation services and increased analytical services.

Nitto Avecia also launched their OliGrow unit in 2013, to offer fast, reliable, early stage oligo support focused on R&D and pre-clinical programs. Through its extended portfolio of services, the OliGrow unit focuses on quick turnaround time, competitive pricing, and phase-appropriate quality standards. The OliGrow unit operates with dedicated staffing and laboratories within the Cincinnati facility and is supported by Nitto Avecia’s high level of oligo expertise and customer service. In just over 6 months of operation Nitto Avecia’s OliGrow unit has produced more than 100 sequences for over 20 clients, and in 2014 they expect to see even stronger demand as interest continues to grow.

Detlef Rethage, President of Nitto Avecia, says, “Our clients are pleased with the integration of the Cincinnati, OH and Milford, MA sites, as well as the additional services, capacity and resources Nitto Avecia now offers. Our goal in 2014 is to grow our Cincinnati site >25%, as we did in 2013, while at the same time expanding our capacity in Milford.” Nitto Avecia is committed to building even more value for customers, from early pre-clinical research to commercial production and market launch.

About Nitto Denko Avecia Inc.:
Nitto Avecia is a drug development and manufacturing services company with headquarters in Milford, MA, and is a part of Nitto, Japan’s leading diversified materials manufacturer. Nitto Avecia is a recognized leader in the oligonucleotide therapeutic market, and with the acquisition of Girindus America’s contract manufacturing business in 2013 has added radiochemistry and small molecule API development and manufacturing to its portfolio of services. Nitto Avecia’s oligonucleotide facilities (in Milford, MA, and Cincinnati, OH) support DNA and RNA-based therapeutics throughout their lifecycle, and include such services as process and analytical development and pre-clinical production through large scale cGMP commercial manufacturing. To see what Nitto Avecia can do for your business, visit http://www.avecia.com.


Contact

Attachments